Emerging studies suggest Retatrutide , a dual agonist targeting both the gut-brain axis and GIP , could represent a promising development for body loss . Early clinical tests have shown considerable https://getretatrutideaustralia.com/blog/retatrutide-vs-tirzepatide-semaglutide